FOR PEOPLE WITH HEMOPHILIA A WITH OR WITHOUT FACTOR VIII INHIBITORS

Join us for an educational session on HEMLIBRA®



What is HEMLIBRA?

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. Carefully follow your healthcare provider's instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. HEMLIBRA may cause serious side effects when used with activated prothrombin complex concentrate (aPCC; FEIBA®), including thrombotic microangiopathy (TMA), and blood clots (thrombotic events). If aPCC (FEIBA®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (FEIBA®) total.

Please see the HEMLIBRA full Prescribing Information and Medication Guide for Important Safety Information, including **Serious Side Effects**.

HEMLIBRA
emicizumab-kxwh
injection for subcutaneous use
150 mg/mL

Exploring HEMLIBRA (ambassador version)

Tuesday, October 29, 2019
Arrival Time - 6:00 PM
Start Time - 6:30 PM

Dinner to be served

Hosted by:
Bobbi Sellers
Genentech Hemophilia Community Clinical Educator

Bellacino's Pizza & Grinders
2856 South Glenstone Avenue
Southeast Springfield, MO 65804

Self-parking

Hear from:
Michael Silvey, DO, Childrens Mercy Hospital

Hubert T, Patient Ambassador

Register **today** for this educational program.

RSVP to Midwest Hemophilia Association at

mhaevents@midwesthemophilia.org by Saturday, October 26, 2019

This program, sponsored by Genentech, will not provide medical advice.
Speak with your healthcare provider if you have questions about your medical condition or treatment.

How should I use HEMLIBRA?

- **Stop (discontinue) prophylactic use of bypassing agents the day before starting HEMLIBRA prophylaxis.**
- **You may continue prophylactic use of factor VIII for the first week of HEMLIBRA prophylaxis.**

What should I know about lab monitoring?

HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and may cause a false reading. Talk to your healthcare provider about how this may affect your care.

The most common side effects of HEMLIBRA include: redness, tenderness, warmth, or itching at the site of injection; headache; and joint pain.

These are not all of the possible side effects of HEMLIBRA. Speak to your healthcare provider for medical advice about side effects.

You may report side effects to the FDA at **(800) FDA-1088** or **www.fda.gov/medwatch**. You may also report side effects to Genentech at **(888) 835-2555**.

Please see the HEMLIBRA full Prescribing Information and Medication Guide for Important Safety Information, including **Serious Side Effects**.

Genentech
A Member of the Roche Group

HEMLIBRA™
emicizumab-kxwh
injection for subcutaneous use
150 mg/mL